Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06328062

Comparing Efficiency of Mirogabalin and Pregabalin in Primary TKA

The goal of this RCT is to compare efficacy between mirogabalin and pregabalin in pain reducing after unilateral primary total knee arthroplasty.

The main question[s] it aims to answer are:

• Does mirogabalin have better pain reduction than pregabalin after unilateral primary total knee arthroplasty.

Participants will randomized to mirogabalin or pregabalin group and will take the drug for 6 weeks after TKA. Researchers will compare to pregabalin group to see pain and functional outcomes after TKA.

Recruiting

Interested in participating?

Request Info

Key information

Age range

50 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Thammasat University Hospital

Khlong Luang, Changwat Pathum Thani, 12120, Thailand

Location status: Recruiting

Location contact

Krit Boontanapibul, M.D.

PRINCIPAL_INVESTIGATOR

Yot Tanariyakul, M.D.

CONTACT

[email protected]

6683930257

Yot Tanariyakul, M.D.

PRINCIPAL_INVESTIGATOR

About this study

After surgery is complete, you will be randomly assigned to receive painkillers Mirogabalin or Pregabalin along with other standard medications.

Surgery by Mirogabalin group: Participants received 5 mg of mirogabalin, taken as half a tablet, every day.

Twice a day, after breakfast and dinner, for 6 weeks. In the pregabalin group: Participants received 50 mg of pregabalin, one tablet taken daily.

Twice a day, after breakfast and dinner, for 6 weeks

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 50-85 years old
  • Unilateral primary osteoarthritis undergoing primary TKA
  • ASA I-III

Exclusion criteria

  • GFR <60
  • Allergy to drug in this study
  • Cannot underwent spinal anesthesia and adductor canal block
  • Taking gabapentinoid within 3 months before surgery
  • History of previous knee surgery
  • Severe liver disease

Treatment and study plan

Mirogabalin

Drug

Participants will receive 5 mg of mirogabalin, taken as half a tablet, every day twice a day, after breakfast and dinner, for 6 weeks.

Pregabalin

Drug

Participants will receive 50 mg of pregabalin, taken as a tablet, every day twice a day, after breakfast and dinner, for 6 weeks.

Primary outcomes

  1. Pain score

    Time frame: Every 6 hours after surgery for 2 days, then twice a day for 2 weeks, then once a week until 12 week after surgery.

    Visual analog scale at rest and motion (0-100 points, 0 mean best, 100 mean worst)

Secondary outcomes

  1. Morphine consumption

    Time frame: 72 hours after surgery

    Total morphine consumption in hospital (mg)

  2. Range of motion

    Time frame: 24 hour, 48 hour, 2 week, 6 week and 12 week after surgery

    Using long arm goniometer (degrees)

  3. Knee society score

    Time frame: 2 week, 6 week and 12 week after surgery

    report in point (0-100, 0 mean worst, 100 mean best)

  4. Knee injury and Osteoarthritis Outcome Score (KOOS)

    Time frame: 2 week, 6 week and 12 week after surgery

    report in point (0-100, 0 mean worst, 100 mean best)

  5. Sedation score

    Time frame: 24 hour, 48 hour, 2 week, 6 week and 12 week after surgery

    report in point (0-100, 0 mean best, 100 mean worst)

  6. Incidence of Somnolence and dizziness

    Time frame: everyday until 14 days then once a week until 12 weeks after surgery

    Using scale "Mild, moderate and severe"

  7. Total hospital stay

    Time frame: up to 1 week

    Number of days the patient stays for surgery

Study contacts

Contact information is provided by the study sponsor or research team.

Yot Tanariyakul, M.D.

CONTACT

[email protected]

+66863930257

Sponsors and collaborators

Lead sponsor

Thammasat University Hospital

Other

Registry information

Official study title

Comparison Efficacy of Mirogabalin and Pregabalin in Total Knee Arthroplasty. a Randomized Controlled Trial

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Mar 25, 2024
Registry last updated
Apr 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.